<?xml version='1.0' encoding='utf-8'?>
<document id="27138546"><sentence text="An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects."><entity charOffset="111-132" id="DDI-PubMed.27138546.s1.e0" text="4β-Hydroxycholesterol" /></sentence><sentence text="The objectives of this analysis were to establish the exposure-response relationship between plasma rifampicin and 4β-hydroxycholesterol (4βHC) concentration and to estimate the effect of weak, moderate, and potent CYP3A induction"><entity charOffset="100-110" id="DDI-PubMed.27138546.s2.e0" text="rifampicin" /><entity charOffset="115-136" id="DDI-PubMed.27138546.s2.e1" text="4β-hydroxycholesterol" /><entity charOffset="138-142" id="DDI-PubMed.27138546.s2.e2" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.27138546.s2.e0" e2="DDI-PubMed.27138546.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27138546.s2.e0" e2="DDI-PubMed.27138546.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s2.e0" e2="DDI-PubMed.27138546.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27138546.s2.e1" e2="DDI-PubMed.27138546.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s2.e1" e2="DDI-PubMed.27138546.s2.e2" /></sentence><sentence text=" Plasma rifampicin and 4βHC concentration-time data from a drug-drug interaction study with rifampicin 600 mg were used for model development"><entity charOffset="8-18" id="DDI-PubMed.27138546.s3.e0" text="rifampicin" /><entity charOffset="23-27" id="DDI-PubMed.27138546.s3.e1" text="4βHC" /><entity charOffset="92-102" id="DDI-PubMed.27138546.s3.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.27138546.s3.e0" e2="DDI-PubMed.27138546.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27138546.s3.e0" e2="DDI-PubMed.27138546.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s3.e0" e2="DDI-PubMed.27138546.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27138546.s3.e1" e2="DDI-PubMed.27138546.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s3.e1" e2="DDI-PubMed.27138546.s3.e2" /></sentence><sentence text=" An indirect response model with an effect compartment described the relationship between rifampicin and 4βHC concentrations"><entity charOffset="90-100" id="DDI-PubMed.27138546.s4.e0" text="rifampicin" /><entity charOffset="105-114" id="DDI-PubMed.27138546.s4.e1" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.27138546.s4.e0" e2="DDI-PubMed.27138546.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27138546.s4.e0" e2="DDI-PubMed.27138546.s4.e1" /></sentence><sentence text=" The model predicted that the equilibration t1/2 and 4βHC t1/2 were 72"><entity charOffset="53-56" id="DDI-PubMed.27138546.s5.e0" text="4βHC" /></sentence><sentence text="8 and 142 hours, respectively" /><sentence text=" EM50 and Emax of rifampicin induction were 32"><entity charOffset="18-28" id="DDI-PubMed.27138546.s7.e0" text="rifampicin" /></sentence><sentence text="6 μg and 8" /><sentence text="39-fold, respectively" /><sentence text=" The population PK-PD model was then used to simulate the effects of rifampicin 10, 20, and 100 mg on plasma 4βHC for up to 21 days, in which rifampicin 10, 20, and 100 mg were used to represent weak, moderate, and strong inducers, respectively"><entity charOffset="69-79" id="DDI-PubMed.27138546.s10.e0" text="rifampicin" /><entity charOffset="142-152" id="DDI-PubMed.27138546.s10.e1" text="rifampicin" /><entity charOffset="109-118" id="DDI-PubMed.27138546.s10.e2" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.27138546.s10.e0" e2="DDI-PubMed.27138546.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27138546.s10.e0" e2="DDI-PubMed.27138546.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27138546.s10.e0" e2="DDI-PubMed.27138546.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s10.e2" e2="DDI-PubMed.27138546.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27138546.s10.e2" e2="DDI-PubMed.27138546.s10.e1" /></sentence><sentence text=" The model-predicted median (5th, 95th percentiles) 1" /><sentence text="13 (1" /><sentence text="04, 1" /><sentence text="44)-, 1" /><sentence text="28 (1" /><sentence text="10, 1" /><sentence text="71)-, and 2" /><sentence text="10 (1" /><sentence text="45, 3" /><sentence text="49)-fold increases in plasma 4βHC after 14-day treatment with rifampicin 10, 20, and 100 mg, respectively"><entity charOffset="62-72" id="DDI-PubMed.27138546.s20.e0" text="rifampicin" /><entity charOffset="29-38" id="DDI-PubMed.27138546.s20.e1" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.27138546.s20.e1" e2="DDI-PubMed.27138546.s20.e1" /><pair ddi="false" e1="DDI-PubMed.27138546.s20.e1" e2="DDI-PubMed.27138546.s20.e0" /></sentence><sentence text=" A new drug candidate can likely be classified as a weak, moderate, or strong inducer if baseline-normalized plasma 4βHC increases by &lt;1"><entity charOffset="116-119" id="DDI-PubMed.27138546.s21.e0" text="4βHC" /></sentence><sentence text="13-, 1" /><sentence text="13- to 2" /><sentence text="10-, or &gt;2" /><sentence text="10-fold, respectively, after 14 days of dosing" /><sentence text="" /></document>